

ATENT COOPERATION TREAT

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

MACDOUGALL, Donald, Carmichael
Marks & Clerk
19 Royal Exchange Square
Glasgow G1 3AE
GRANDE BRETAGNE

PCT

NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Rule 71.1)

Date of mailing

(day/month/year)

12.01.2005

Applicant's or agent's file reference

PCCPP12998PC

IMPORTANT NOTIFICATION

International application No.

PCT/GB 03/03199

International filing date (day/month/year)

28.07.2003

Priority date (day/month/year)

26.07.2002

Applicant

UNIVERSITY COURT OF THE UNIVERSITY OF EDINB..et al

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.
4. **REMINDER**

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

The applicant's attention is drawn to Article 33(5), which provides that the criteria of novelty, inventive step and industrial applicability described in Article 33(2) to (4) merely serve the purposes of international preliminary examination and that "any Contracting State may apply additional or different criteria for the purposes of deciding whether, in that State, the claimed inventions is patentable or not" (see also Article 27(5)). Such additional criteria may relate, for example, to exemptions from patentability, requirements for enabling disclosure, clarity and support for the claims.

Name and mailing address of the international preliminary examining authority:



European Patent Office
D-80298 Munich
Tel. +49 89 2399 - 0 Tx: 523656 eptnu d
Fax: +49 89 2399 - 4465

Authorized Officer

Papiol Rovira, M



Tel. +49 89 2399-7199



PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT
(PCT Article 36 and Rule 70)

Applicant's or agent's file reference PC/CP/12998PC		FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/PEA/416)	
International application No. PCT/GB 03/03199	International filing date (day/month/year) 28.07.2003	Priority date (day/month/year) 26.07.2002	
International Patent Classification (IPC) or both national classification and IPC C07K14/765			
Applicant UNIVERSITY COURT OF THE UNIVERSITY OF EDINB..et al			
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 5 sheets, including this cover sheet.</p> <p><input checked="" type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of 4 sheets.</p>			
<p>3. This report contains indications relating to the following items:</p> <p>I <input checked="" type="checkbox"/> Basis of the opinion</p> <p>II <input type="checkbox"/> Priority</p> <p>III <input type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</p> <p>IV <input type="checkbox"/> Lack of unity of invention</p> <p>V <input checked="" type="checkbox"/> Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</p> <p>VI <input type="checkbox"/> Certain documents cited</p> <p>VII <input type="checkbox"/> Certain defects in the international application</p> <p>VIII <input type="checkbox"/> Certain observations on the international application</p>			
Date of submission of the demand 25.02.2004		Date of completion of this report 12.01.2005	
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 upmu d Fax: +49 89 2399 - 4465		Authorized Officer Paresce, D Telephone No. +49 89 2399-6995 	

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**International application No. **PCT/GB 03/03199****I. Basis of the report**

1. With regard to the elements of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

Description, Pages

1-35 as originally filed

Sequence listings part of the description, Pages

1-7 as originally filed

Claims, Numbers

1-18 filed with the demand

Drawings, Sheets

1-19 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☒ contained in the international application in written form.
- ☒ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☒ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☒ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**International application No. **PCT/GB 03/03199**

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)).

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes: Claims	1-2, 4-16
	No: Claims	3, 7-18
Inventive step (IS)	Yes: Claims	1-2, 4-16
	No: Claims	
Industrial applicability (IA)	Yes: Claims	1-18
	No: Claims	

2. Citations and explanations

see separate sheet

INTERNATIONAL PRELIMINARY

International application No. PCT/GB 03/03199

EXAMINATION REPORT - SEPARATE SHEET

Re Item V

Reasoned statement with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

Reference is made to the following documents:

D1: WO 02/05645 A (NEW CENTURY PHARMACEUTICALS) 24 January 2002 (2002-01-24)

D2: WO 99/28348 A (RUKER FLORIAN ;HO JOSEPH X (US); CARTER DANIEL C (US); NEW CENTURY) 10 June 1999 (1999-06-10)

D1 (W0205645) discloses a modified serum albumin in which the affinity to trace metals such as nickel and/or copper is reduced or eliminated. The modified serum albumin is either truncated by at least one amino acid at its n-terminal end or is mutated in such a way as to disrupt the metal binding site of the serum albumin binding site VI. Mutations to this binding site include elongation, insertion or other changes to the n-terminal end, such as to the histidine at amino acid position 3, which either sterically hinder the binding site VI or eliminate vital binding interactions, and thus reduce the affinity of this region to metals such as nickel or copper.

D2 (W09928348) discloses a recombinant serum albumin which has been modified from human serum albumin, in the heme binding region, so as to have the ability when bound to heme to be capable of reversibly binding oxygen. In the disclosed modified albumin at least one of the hydrophobic binding residues responsible for the binding of heme in the serum albumin-heme binding region is replaced with a hydrophilic amino acid residue which is histidine or glutamine.

The IPEA is of the opinion that the modified serum albumins disclosed in D1 or D2 would fall under the scope of claims 3, 17-18. The scope of claim 3 is broad and unclear (see below) and therefore, could encompass the modified serums disclosed in the prior art. The method of claims 17-18 has been previously described in examples 1-2, p. 12-13 of D1 or example 1, p. 16-17 of D2.

The subject-matter of claims 1-2, 4-16 has not been made available to the public by any of the available prior art documents and can therefore be regarded as novel. The subject-matter of claims 1-2, 4-16 cannot be derived from the available prior art in an obvious manner and therefore complies with the requirements of Article 33(3) PCT.

INTERNATIONAL PRELIMINARY

International application No. PCT/GB 03/03199

EXAMINATION REPORT - SEPARATE SHEET

The expression "substantially" used in claims 1, 3, 5 is not suitable to clearly define the scope of the claim, because it is without technical significance and its vagueness makes it entirely open to individual interpretation.

Claims 3, 18 contain references to the description and/or the drawings (i.e. to Table 1). According to Rule 6.2(a) PCT, claims should not contain such references except where absolutely necessary, which is not the case here.

10/523312

Printed: 15-01-2004

CAMSPAMD

EPQ 166 01 PCTGB 03 03 199

JT12 Rec'd PCT/PTO 26 JAN 2005

37

CLAIMS

1. An isolated mutant human serum albumin substantially comprising the amino acid sequence:

DAHKSEVAHRFKDLGEENFKALVLIAFAQX₅LQQCPFEDHV
 KLVNEVTEFAKTCVADES AENCCKSLX₁TLFGDKLCTVATL
 RETYGEMADCCAKQEPERX₂X₃CFX₆QHKDDNPNLPLRVPE
 VDVMTAFHDNEETFLKKYLYEIARRX₉PYFYAPELLFFAKR
 YKAAFTECCQAADKAACLLPKLDEL RDEGKASSAKQRLKC
 ASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLT
 VX₁₀TECCX₃X₇X₄LLECADDRADLAKYICENQDSISSKLKEC
 CEKPLLEKSX₁₁CIAEVENDEMPADLPSLAADFVESKDVCKN
 YAEAKDVFLGMFLYEYARRHPDYSVLLLLRLAKTYETTL
 KCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCLEFEQLG
 EYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCK
 HPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTES
 LVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQ
 IKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKAD
 DKETCFAEEGKKLV AASQAALGL

wherein X₁ is other than H; X₂ is other than N, X₃ is other than H, X₄ is other than D; X₅ is other than Y; X₆ is other than L; X₇ is other than G, X₈ is other than E, X₉ is other than H, X₁₀ is other than H, and X₁₁ is other than H, such that said mutant displays an altered metal binding affinity and/or other physiological characteristic(s) with respect to native human serum albumin.

2. The mutant according to claim 1 wherein the other physiological characteristic(s) are a change in cell adhesion to a substrate, percentage viability of cell and/or cell growth of cells in culture.

3. An isolated mutant mammalian serum albumin substantially comprising one of the sequences as shown in Table 1 wherein at least one of the residues identified by grey-shading is mutated such that said mutant serum albumin displays an altered metal binding affinity or other physiological characteristic(s) with respect to the native sequence from which the mutant is derived.

AMENDED SHEET

04-03-2004

Printed: 03-2004

CLMSFAMD

EP00016601 PCTEP 03/03/99

38

4. An isolated mutant serum albumin according to any preceding claim which is at least 90% identical with the native sequence from which the mutant is derived.

5. The mutant serum albumin according to any preceding claim which is substantially similar in terms of general overall folding with respect to the native serum albumin from which it is derived.

6. The mutant serum albumin according to any preceding claim wherein the altered metal binding affinity is a decrease or increase in metal binding affinity.

7. The mutant according to any preceding claim wherein the metal is zinc.

8. The mutant according to any preceding claim comprising at last one of the following mutations:

$X_1 \Rightarrow$ A, F, G, I, K, L, N, P, Q, R, S, T, V, W, Y, C, D, E

$X_2 \Rightarrow$ A, F, G, I, K, L, P, Q, R, S, T, V, W, Y, C, D, E, H

$X_3 \Rightarrow$ A, F, G, I, K, L, N, P, Q, R, S, T, V, W, Y, C, D, E

$X_4 \Rightarrow$ A, F, G, I, K, L, N, P, Q, R, S, T, V, W, Y, C, E, H

$X_5 \Rightarrow$ C, D, E, H

$X_6 \Rightarrow$ C, D, E, H

$X_7 \Rightarrow$ C, D, E, H

$X_8 \Rightarrow$ A, C, F, G, H, I, K, L, N, P, Q, R, S, T, V, W, Y

$X_9 \Rightarrow$ A, D, E, F, G, I, K, L, N, P, Q, R, S, T, V, W, Y

$X_{10} \Rightarrow$ A, D, E, F, G, I, K, L, N, P, Q, R, S, T, V, W, Y

$X_{11} \Rightarrow$ A, D, E, F, G, I, K, L, N, P, Q, R, S, T, V, W, Y

9. The mutant according to any preceding claim comprising at least one mutation at X_1 , X_2 , X_3 or X_4 .

Filed: 03-2004

CLMSPAMD

EP: 166.04 PCTGB 03.03.99

39

10. A mutant human serum albumin comprising the mutation Asn 99His, Asn99Asp or His67Ala.

11. A nucleic acid sequence capable of encoding a mutant serum albumin according to any preceding claim.

12. An expression cassette comprising a promoter operably linked to a nucleic acid sequence according to claim 11.

13. A pharmaceutical composition comprising a mutant serum albumin, a nucleic acid sequence or an expression cassette according to any preceding claim and a pharmaceutically acceptable carrier therefore.

14. A cell culture medium comprising a mutant serum albumin, a nucleic acid sequence or an expression cassette according to any one of claims 1 – 12.

15. Use of a mutant serum albumin, nucleic acid or expression cassette according to any one of claims 1 – 12 in culturing of cells for affecting cell adhesion and/or cell growth characteristics.

16. A method of altering growth characteristics of cells in cell culture comprising the step of culturing cells in cell culture in the presence of a mutant serum albumin according to any one of claims 1-12.

17. A method of obtaining a mutant serum albumin which displays an altered metal binding affinity and/or other physiological characteristic(s) with respect to a native albumin from which the mutant has been derived, comprising the steps of:

- providing a nucleic acid sequence encoding a nucleic albumin polypeptide;
- conducting a mutagenesis reaction on said nucleic acid in order to alter said nucleic acid whereby said altered nucleic acid sequence encodes a mutant albumin polypeptide comprising at least one mutation with respect to said native albumin;

Printed: 11-03-2004

CLMSPAMD

EP0 1660 PCTGB 03-03-99

- c) expressing said mutant albumin polypeptide and detecting whether or not said mutant albumin displays an altered metal binding and/or other physiological characteristic(s).
18. The method according to claim 17 wherein the mutant albumin comprises at least one mutation to residues $X_1 - X_{11}$ as shown in Table 1.

04-10-2004


**BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE
UNITED STATES PATENT AND TRADEMARK OFFICE**

LIMITED RECOGNITION UNDER 37 CFR § 11.9(b)

Richard G. A. Bone is hereby given limited recognition under 37 CFR § 11.9(b) as an employee of Morgan, Lewis & Bockius LLP, to prepare and prosecute patent applications wherein the patent applicant is the client of Morgan, Lewis & Bockius LLP and the attorney or agent of record in the applications is a registered practitioner who is a member of Morgan, Lewis & Bockius LLP. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Richard G. A. Bone ceases to lawfully reside in the United States, (ii) Richard G. A. Bone's employment with Morgan, Lewis & Bockius LLP ceases or is terminated, or (iii) Richard G. A. Bone's employment authorization ceases or expires.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Expires: November 11, 2005


Harry I. Moatz
Director of Enrollment and Discipline